ClinicalTrials.Veeva

Menu
T

The University of Sydney | Sydney Eye Hospital

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

KHK4951
Dexamethasone
Ranibizumab
Faricimab
Zimura
KIO-104
AZR-MD-001
Presendin
Bevacizumab
AGTC-501

Parent organization

This site is a part of The University of Sydney

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

15 of 35 total trials

A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

This study will evaluate and compare the safety, efficacy, and tolerability of 2 doses of a recombinant adeno-associated virus vector (AGTC-501/larup...

Enrolling
X-Linked Retinitis Pigmentosa
Drug: Control
Biological: rAAV2tYF-GRK1-hRPGRco

The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-...

Active, not recruiting
Thyroid Eye Disease
Drug: VRDN-001 10 mg/kg
Drug: VRDN-001 3 mg/kg

This study aims to evaluate the efficacy, safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of efgartigimod P...

Enrolling
Thyroid Eye Disease
Other: Placebo PH20 SC
Combination Product: Efgartigimod PH20 SC

Study WR42221 is a Phase IIIb, global, multicenter, randomized, visual assessor-masked study designed to assess the efficacy, safety, and pharmacokin...

Enrolling
Neovascular Age-related Macular Degeneration (nAMD)
Device: Port Delivery System with Ranibizumab
Drug: Ranibizumab

This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of faricimab in pa...

Enrolling
Choroidal Neovascularization Secondary to Pathologic Myopia
Procedure: Sham Procedure
Drug: Faricimab

The goal of this clinical trial is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of VX-01 as stand-alone treatmen...

Enrolling
NPDR - Non Proliferative Diabetic Retinopathy
Diabetic Retinopathy
Drug: VX-01
Drug: Placebo

The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous (SC) satralizumab, a recombinant,...

Active, not recruiting
TED
Thyroid Eye Disease
Drug: Satralizumab
Drug: Placebo

Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO).In people with RVO, a blood...

Active, not recruiting
Macular Edema Secondary to Retinal Vein Occlusion
Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg
Drug: Sham

The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period...

Enrolling
Thyroid Eye Disease
Other: Placebo
Biological: Teprotumumab

This study will be a randomized, vehicle-controlled, double-masked, multiple-dose, parallel-group study to evaluate the efficacy, safety and tolerabi...

Enrolling
Dry Eye
Drug: BTV100 High dose
Drug: BTV100 Low dose

This is a multi-center, open label study to assess the safety, tolerability, and efficacy of KIO-104 administered by IVT injection to the study eye o...

Not yet enrolling
Macular Edema
Drug: KIO-104

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.

Enrolling
Diabetic Macular Edema (DME)
Drug: KHK4951
Drug: Aflibercept Injection

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.

Enrolling
Neovascular Age-Related Macular Degeneration (nAMD)
Drug: Aflibercept Injection
Drug: KHK4951

This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.

Active, not recruiting
Uveitic Macular Edema
Other: Sham
Drug: Vamikibart

The VividWhite Glaucoma Implant (VW-51) is a novel surgical implant designed to treat glaucoma. This study is a 12-month, 65-participant non-comparat...

Enrolling
Glaucoma
Device: VividWhite Glaucoma Implant (VW-51)

Trial sponsors

Roche logo
Ionis Pharmaceuticals logo
Kyowa Kirin logo
N
U
Amgen logo
A
Bayer logo
B
Genentech logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems